English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Evidence exists that cannabis consumption is associated with the development of psychosis. Further, continued cannabis use in individuals with recent onset psychosis (ROP) increases the risk for rehospitalization, high symptom severity and low general functioning. Clear inter-individual differences in the vulnerability to the harmful effects of the drug have been pointed out. These findings emphasize the importance of investigating the inter-individual variability in the role of cannabis use in ROP and to understand how cannabis use relates to subclinical conditions that predate the full-blown disease in clinical high-risk (CHR). Specific symptoms have been linked with continued cannabis consume, still research is lacking on how different factors contribute together to an elevated risk of cannabis relapse. Multivariate techniques have the capacity to extract complex patterns from high dimensional data and apply generalized rules to unseen cases. The aim of the study is therefore to assess the predictability of cannabis relapse in ROP and CHR by applying machine learning to clinical and environmental data. Methods All participants were recruited within the multi-site, longitudinal PRONIA study (www.pronia.eu). 112 individuals (58 ROP and 54 CHR) from 8 different European research centres reported lifetime cannabis consume at baseline and were abstinent for at least 4 weeks. We defined cannabis relapse as any cannabis consume between baseline and 9 months follow-up reported by the individual. To predict cannabis relapse, we trained a random forest algorithm implemented in the mlr package, R version 3.5.2. on 183 baseline variables including clinical symptoms, general functioning, demographics and consume patterns within a repeated-nested cross-validation framework. The data underwent pre-processing through pruning of non-informative variables and median-imputation for missing values. The number of trees was set to 500, while the number of nodes, sample fraction and mtry were optimized. All hyperparameters were tuned with the model-based optimization implemented in the mlrMBO R package. Results After 9 months 50 individuals (48 % ROP, 52 % CHR) have relapsed on cannabis use. Relapse was over all timepoints associated with more severe psychotic symptoms measured by PANSS positive and PANSS general (p&amp;lt;0.05) and a significant interaction between positive symptoms and time of measurement (p&amp;lt;0.05). Our random forest classifier could predict cannabis relapse with a balanced accuracy, sensitivity, and specificity of, respectively, 66.5 %, 66.0 % and 67.0 %. The most predictive variables were a higher cumulative frequency of cannabis consumption in the last 3 months, worse general functioning in the last month, higher density of place of living, younger age and a shorter interval time since the last consumption. Discussion Our results using a state-of-the-art machine learning approach suggest that the multivariate signature of baseline demographic and clinical data could predict follow up cannabis relapse above chance level in CHR and ROP. Our findings revealing that cannabis relapse is associated with more severe symptoms is in line with previous literature and emphasizes the need for targeted treatment towards abstinence from cannabis. The information of demographic and clinical patterns might be useful in order to specifically address therapeutic strategies in individuals at higher risk for relapse. This might include special programs for younger patients and taking into account the place of living, like urban areas. Further research is needed in order to validate our model in an independent sample.

S94. PREDICTION OF CANNABIS RELAPSE IN CLINICAL HIGH-RISK INDIVIDUALS AND RECENT ONSET PSYCHOSIS - PRELIMINARY RESULTS FROM THE PRONIA STUDY